Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2008-06-06

Clinical Trial Update: Efficacy of Zinc in Reducing Hyperbilirubinemia Among High Risk Neonates - A Double Blind Randomized Trial [Phase 1, Phase 2]

View source ↗

Summary

A Phase 1/2 double-blind trial evaluating whether zinc reduces hyperbilirubinemia in high-risk neonates has been completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Zinc sulfate (Zinc sulfate)

Snippet

Sponsor: All India Institute of Medical Sciences | Conditions: Neonatal Jaundice | Phase 1, Phase 2 | Status: COMPLETED